RedHill Biopharma's partner, Gaelan Medical, has received marketing approval from the United Arab Emirates (UAE) Ministry of Health for Talicia.
The approval makes Talicia the first approved rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori.
Talicia, an innovative fixed-dose oral capsule, which combines two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) called omeprazole. This distinctive formulation has earned approval from the U.S. FDA for effectively treating H. pylori infection in adults.
Talicia stands as the new low-dose rifabutin-centred treatment endorsed for H. pylori infection, distinctly engineered to confront the bacterium's formidable resistance to conventional antibiotics.
H. pylori, a bacterial infection, impacts a majority of the U.S. population, with around two million annual patients undergoing treatment. Globally, over 50 percent of individuals are affected. It remains as the predominant risk contributor to gastric cancer and significantly heightens susceptibility to peptic ulcer disease and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!